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Edited by Laszlo Nagy and Peter TontonozAbstract Subclinical inﬂammation is a candidate etiological
factor in the pathogenesis of metabolic syndrome and in the pro-
gression of atherosclerosis. A central role for activated macro-
phages has been elucidated recently as important regulators of
the inﬂammatory process in atherosclerosis. Macrophage diﬀer-
entiation and function can be modulated by a class of transcrip-
tion factors termed nuclear receptors. These are activated by
intermediary products of basic metabolic processes. In this
review the contribution of peroxisome proliferator-activated
receptors and liver X receptors to macrophage functions in
inﬂammation and lipid metabolism will be discussed in light of
their roles in macrophages during atherosclerosis.
In the past decade much eﬀort has been made to understand
the mechanisms how lipids are handled by macrophages and
how inﬂammation could promote the atherogenic process. Here,
we also provide an overview of these two ﬁelds.
 2007 Federation of European Biochemical Societies.
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Atherosclerosis1. Introduction
Disturbances in the basic metabolism lead to several disease
states in western societies. Altered lipid turnover in the body
results in pathological abnormalities. Among these, cardiovas-
cular disease is the leading cause of death therefore under-
standing the progression of atherosclerosis has placed lipid
metabolism and inﬂammation in the limelight.
Atherosclerosis is a degenerative disease of the tunica intima
within arteries characterized by lipid accumulation in the wall
initially observed by the development of fatty streaks within
the subintimal tissues [1]. Development of fatty streaks is con-
sidered to be driven by a pathogenic interaction between circu-Abbreviations: PPAR-c, peroxisome proliferator-activated receptor c;
LXR, liver X receptor; DC, dendritic cell; IFN, interferon; IL,
interleukin; LDL, low density lipoprotein; LDLR, LDL receptor; SR,
scavenger receptor
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doi:10.1016/j.febslet.2007.11.020lating lipoproteins, hemodynamic factors, endothelial cells,
vascular smooth muscle cells, macrophages, T lymphocytes
and a constellation of metabolic abnormalities including insu-
lin resistance, hypertension, dyslipidemia and central obesity
collectively referred to as metabolic syndrome [2]. Handling
of lipids by lesion macrophages is an important metabolic pro-
cess in the context of hypercholesterolemia and the develop-
ment of atherosclerotic lesions [3–5].
As a ﬁrst step during atherogenesis a disturbance in endothel
function results in the accumulation of low-density lipoprotein
(LDL) in the sub-endothelial matrix. It is not clear how LDL
gets modiﬁed but this leads to the appearance of minimally
oxidized/modiﬁed (mmLDL) and subsequently fully oxidized
LDL (oxLDL) containing multiple oxidized lipid molecules.
Modiﬁed lipoproteins activate both endothelial cells and
monocytes/macrophages resulting in further monocyte migra-
tion into the sub-endothelial space in response to locally
produced chemoattractant molecules and cytokines like inter-
feron c (IFN-c), interleukin-1b (IL-1-b), IL-6, tumor necrosis
factor a (TNF-a) [6]. Macrophages are the ﬁrst cellular com-
ponents in lesion formation, they take up lipid particles
through special cell surface proteins, scavanger receptors
(SRs), as SR-A and CD36 that are not subjected to downreg-
ulation via a feed-back mechanism like LDL receptor. These
processes evoke a characteristic inﬂammatory response by
releasing inﬂammatory molecules to the extracellular environ-
ment such as monocyte chemoattractant protein-1 (MCP-1),
which attract additional macrophages and other cells to the le-
sion [7,8].
Macrophages accumulate lipids from oxLDL leading to
lipid-loaded foam cell formation, the characteristic cells of
the early, cellular phase of lesions (Fig. 1B). Foam cells can
also eliminate lipids from the sub-endothelial space through
ATP-binding cassette transporters such as ABCA1, ABCG1
towards high-density lipoprotein (HDL) but if the transport
is inhibited they accumulate lipids continuously resulting in in-
creased cell death of inﬂammatory cells and the release of
intracellular molecules that lead to a sustained chronic inﬂam-
mation [4,9,10]. This chronic inﬂammation with secreted medi-
ators and growth factors make smooth muscle cells migrate
from the tunica media, proliferate and rearrange extracellular
matrix (Fig. 1B,C). This results in the formation of the late,
ﬁbrous atherosclerotic plaques. This late lesion is characterized
by calciﬁcation (sclerosis), which makes artery wall rigid and
fragile. Finally, the originally stable lesion may change intoblished by Elsevier B.V. All rights reserved.
Fig. 1. The normal and pathological histology of the aortic arch. In
mammals, as in mice (A) and humans (B and C) the aorta and the large
arteries are built up from three tissue layers, the tunica intima (TI)
covering the luminal surface (lu) of the vessels, the tunica media (TM)
containing elastic layers and the tunica adventitia (TA). Human large
arteries often have a subendothelial layer, which grows with age or
atherosclerosis. Both connective tissue and smooth muscle cells are
present in the intima. The border of the intima is delineated by the
internal elastic membrane, which may not be conspicuous because of
the abundance of elastic material in the tunica media (see inset in B).
The tunica adventitia is a relatively thin connective tissue layer. In
mice, mediastinal brown adipose cells (mf) can be involved in the
formation of the tunica adventitia. Fibroblasts are the predominant
cell type and many macrophages are also present. In mice, atheroscle-
rotic plaques naturally cannot evolve, but in human lipid (lp)
accumulation in the so-called fatty streaks of the subendothelial layer
can occur with aging (B). In parallel with the accumulation of modiﬁed
LDL, macrophages invade the tunica intima and diﬀerentiate into
foam cells (fc). The vascular smooth muscle cells start to proliferate
and form a hyalinized ﬁbrous layer (hf) in the luminal surface of the
subendothelial layer. The normal structure of elastic lamellae can be
also degenerated. At the late phase of atheroprogression the subintimal
layer is highly inﬁltrated by foam cells and the extracellular matrix
proteins are degraded and show an eosinophilic hyalinic appearance
(ﬁbrous cap). Remnants of the apoptotic foam cells form a cholesterol
(chol) rich necrotic core. Sections A, B, C are stained with hematox-
ylin–chromotrope, the inset is stained with orcein. Magniﬁcations:
1000· (A), 250· (B and C), 400· (insert).
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factors producing and degrading extracellular elements and
this can easily rupture the covering endothelium leading to
the formation of thrombus and intravascular coagulation.There is growing appreciation that a special group of ligand-
activated transcription factors play key roles in both the met-
abolic as well as the inﬂammatory processes.2. Lipid metabolism of lesion macrophages: the pros and cons for
peroxisome proliferator-activated receptor c (PPAR-c) in
atherogenesis
Nuclear receptors are ligand-activated transcription factors.
Small lipid-soluble molecules activate them. Members of this
family can be located in the cytosol like classic steroid recep-
tors (e.g. glucocorticoid receptor) or in the nucleus binding
to the response elements of their target genes. Upon ligand
binding receptors induce transcription of their target genes.
Here, we are focusing on PPAR-c and liver X receptor
(LXR) since they have been shown to play a substantial role
in lesion macrophages during atherosclerosis. Both of them
form heterodimer with a common partner, retinoid X receptor
(RXR).
PPAR-c is most prominently expressed in adipose tissue and
myelomonocytic cells, as macrophages and dendritic cells
(DCs). PPAR-c promotes uptake of oxLDL and subsequent
diﬀerentiation of the macrophages to foam cells [11]. It is well
known, that PPAR-c is expressed in foam cells of atheroscle-
rotic lesion [11,12]. Oxidized but not native LDL promotes
its own uptake via scavenger receptor CD36 by PPAR-c [11].
Two components from oxLDL, 9-hydroxy octadecadienoic
acid (9-HODE) and 13-HODE were identiﬁed as endogenous
activators and bona ﬁde ligands for PPAR-c [13]. There are
also other scavenger receptors involved in LDL/oxLDL up-
take, which will be discussed later. Thus, the consequence of
oxLDL internalization is the activation of PPAR-c that en-
hances further expression of CD36.
To provide genetic evidence that PPAR-c is required for
macrophage development and CD36 expression PPAR-c-deﬁ-
cient embryonic stem (ES) cells were generated. Surprisingly,
these can be diﬀerentiated into macrophages in vitro. In chime-
ric mice generated with mutant ES cells PPAR-c-deﬁcient cells
are also able to contribute to the macrophage lineage in vivo
[14]. However, retroviral transfer of the receptor facilitates
induction of CD36 and oxLDL uptake in response to
PPAR-c-speciﬁc agonists. There is no change in the mRNA
level of CD36 when PPAR-c-deﬁcient macrophages are treated
with synthetic agonists such as thiazolidinediones (TZDs).
These suggest that PPAR-c is not necessary for macrophage
development but required for the induction of CD36 and
oxLDL uptake.
The model above would suggest that PPAR-c is a pro-ath-
erogenic factor. To deﬁne the in vivo role of PPAR-c in ath-
erogenesis PPAR-c null bone marrow was transplanted into
LDL receptor (LDLR) knockout mice, a murine model of ath-
erosclerosis. Although animals received cholesterol-rich diet
for 8 weeks, plasma total cholesterol levels were similar in con-
trol and PPAR-c null bone marrow transplanted mice, how-
ever the degree of atherosclerosis was signiﬁcantly increased
in PPAR-c-deﬁcient bone marrow transplanted recipients [15].
TZDs were also reported to inhibit the development of ath-
erosclerosis in LDLR-deﬁcient male mice [16]. Chen and col-
leagues showed similar results in ApoE null mice, another
murine model of atherosclerosis [17]. Targeted disruption of
the PPAR-c gene in macrophages resulted in reduced total
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signiﬁcantly decreased from macrophages elicited by thiogly-
colate in mutant mice [18,19].
To summarize, these observations suggest that PPAR-c in
macrophages is rather anti-atherogenic, it induces cholesterol
removal and its synthetic agonists also exert anti-atherogenic
eﬀects.3. Coupling of the signaling events of PPAR-c and LXR: role for
endogenous ligands
As detailed above, PPAR-c enhances uptake of its own
ligand via oxLDL but it can also induce cholesterol eﬄux from
macrophages via several mechanisms. An important one is the
induction of another nuclear receptor, LXR-a [15], which in
turn activates expression of a set of genes involved in choles-
terol eﬄux and transport. Two LXR proteins (a and b) are
known to exist in mammals. LXR-a is highly expressed in
the liver but signiﬁcant levels are present in macrophages, kid-
ney, intestine, spleen and adrenal glands. LXR-b is more ubiq-
uitously expressed and it has been found in nearly every tissue
examined [20]. Several oxysterols have been identiﬁed as
endogenous ligands for LXR.
LXRs have been implicated in the regulation of cholesterol
metabolism and clearance [21,22] and recently in inﬂammation
[23,24]. Mice lacking LXR-a lose their ability to respond nor-
mally to dietary cholesterol and are unable to tolerate any
amount of cholesterol in excess of that they synthesize de novo
[25–27]. These mice develop severe atherosclerosis. Serum and
hepatic cholesterol levels and lipoprotein proﬁles of choles-
terol-fed animals showed no signiﬁcant diﬀerences between
LXR-b/ and wild-type mice. LXR-b/ mice – in contrast
to LXR-a/ mice – maintain their resistance to dietary cho-
lesterol. Synthetic LXR agonist was shown to reduce athero-
sclerosis in two mouse models, in ApoE/ and in LDL
receptor / mice [28].
Among LXR target genes there are lipid transporters, such
as ABCA1 and ABCG1, members of the ATP-binding cassette
family of transporter proteins that are likely to be responsible
for cholesterol eﬄux [29]. They are highly expressed in lipid-
loaded macrophages [29]. Cholesterol clearance is impaired
in ﬁbroblasts isolated from patients with Tangier-disease, a
disease characterized by mutations in ABCA1 gene and
marked cholesterol accumulation in macrophages and other
reticuloendothelial cells [30–32] which suggests that ABCA1
has a pivotal role in cholesterol eﬄux. Several studies reported
that LXRs mediate cholesterol eﬄux by inducing cholesterol
transporters ABCA1, ABCG1 and later ABCG5 and ABCG8
[21,29,33–35].
It is also known that oxLDL has cytotoxic eﬀects on macro-
phages [36]. Induction of apoptosis inhibitor of macrophages
(AIM) by LXR in mouse supports macrophage survival in
the lesion, which allows macrophages to harbor large amount
of cholesterol [37–39].
These observations highlight the importance of LXR activa-
tion in foam cells. A number of oxysterols were identiﬁed as
potential endogenous ligands for LXR [22,25,40–42]. One of
these, 27-hydroxycholesterol is produced by a p450 enzyme
CYP27, which is a mitochondrial enzyme involved in alterna-
tive bile acid synthesis [43,44] and was reported to be associ-
ated with atherosclerotic lesions [45,46]. Mutation of theenzyme leads to a human disease cerebrotendinous xanthoma-
tosis (CTX), a rare sterol-storage disease characterized by xan-
thomas in tendons and also in the central nervous system
leading to ataxia, spinal cord paresis, neurological dysfunc-
tions, normolipidemic xanthomatosis and accelerated athero-
sclerosis [47–49]. We found that retinoid receptors and
PPAR-c induce the expression of CYP27 resulting in increased
production 27-hydroxycholesterol in macrophages which acti-
vates LXR and enhances cholesterol eﬄux from macrophages
through ABC transporters [50].
Thus, it seems that oxLDL uptake leads to the activation of
PPAR-c in macrophages, which in turn enhances cholesterol
eﬄux via the induction of LXR and CYP27.4. Alternative mechanisms for PPAR-driven lipid transport in
macrophages
Besides the PPAR-c-induced LXR activation there are fur-
ther possible mechanisms that could modulate nuclear recep-
tor-regulated lipid transport in macrophages.
Another mechanism of transcriptional regulation exists at
the promoter level of target genes. Activity of the nuclear
receptors depends on the recruitment and exchange of co-
repressors and co-activators. Recently, a co-factor, adipocyte
enhancer-binding protein 1 (AEBP1) was shown to act as a
transcriptional repressor that impedes macrophage cholesterol
eﬄux, promotes foam cell formation via PPAR-c and LXR-a
down-regulation. Contrary to AEBP1-deﬁciency, AEBP1
overexpression in macrophages is accompanied by decreased
expression of PPAR-c, LXR-a and their target genes with con-
comitant elevation of pro-inﬂammatory cytokines [51].
It was also reported that activation of PPAR-c reduced
cholesterol esteriﬁcation, induced expression of ABCG1 and
stimulated HDL-dependent cholesterol eﬄux in an LXR-inde-
pendent manner [52] suggesting that PPAR-c can both directly
and indirectly (through LXR) induce transcription of ABCG1.5. Summary of the roles of PPARs and LXR in lipid metabolism
of the macrophages
According to the current model, oxLDL activates transcrip-
tion on multiple levels. It transports ligand for PPAR-c and
ligand precursor for LXR. These lipid molecules turn on a spe-
ciﬁc transcription program within the macrophages resulting
in further synthesis of PPAR-c and induction of its target
genes: scavenger receptors, metabolic enzymes, LXR. Conse-
quently, further oxLDL is taken up and reverse cholesterol
transport is also activated through the LXR. Furthermore,
the survival of macrophages is also inﬂuenced by LXR. The
existence of such transcriptional cascade predicts that modula-
tion of one of the elements will aﬀect all the others and the net
eﬀect on cellular cholesterol level depends on the balance
between the inﬂux and eﬄux. In the context of macrophages,
an alteration in the balance between the two processes and
the subsequent overloading of macrophages with lipids results
in foam cell formation. Mutation of PPAR-c, CD36 or other
scavenger receptors, LXR, ABC-transporters result in in-
creased atherosclerosis in both men and mice. However, there
are species-speciﬁc diﬀerences: Cholesterol metabolism of the
men and mice are diﬀerent: the main lipoprotein is the HDL
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regulation of lipid inﬂux and eﬄux by nuclear receptors is also
diﬀerent. CYP27 can be induced by retinoids and PPAR-c
only in human macrophages [50]. Deletion of CYP27 does
not induce atherosclerosis in mice [53–55] only in men
[45,46]. LXR can induce its own transcription only in human
cells [26,56,57]. AIM is regulated by LXR only in mice [37].
There are reports suggesting that PPAR-a and b/d can also
participate in regulatory processes in foam cells. When PPAR-
a, c and b/d agonists were compared, a PPAR-a-speciﬁc
agonist strongly inhibited atherosclerosis, whereas a PPAR-
b/d-speciﬁc agonist failed to inhibit lesion formation. The
PPAR-b/d agonist, GW0742X has potent anti-atherogenic
activity in the LDLR knockout mice [58]. PPAR-b/d functions
as a sensor for VLDL [59] and promotes VLDL-derived fatty
acid catabolism. Unliganded PPAR-b/d suppresses fatty acid
utilization through active repression, which is reversed upon
ligand binding [60,61]. PPAR-b/d agonist reduces expression
of Niemann-Pick C1-like 1 protein (Npc1l1) in the intestine
resulting in lower cholesterol absorption [62]. Based on these
data we can conclude that all three PPAR isotypes have
anti-atherogenic eﬀects.
Analyzing nuclear receptors in macrophages revealed that
PPAR-c and LXR-a have key functions in the regulation.
Nevertheless, many questions remain to be answered about nu-
clear receptor activation.6. Inﬂammation in atherosclerosis: another target for PPAR-c
and LXR
Macrophages are primary inﬂammatory cells regulating
many steps of innate and adaptive immune responses. The
questions how inﬂammation regulates nuclear receptor activity
and how PPAR-c and LXR could inﬂuence inﬂammatory
reactions are the most important ones in the context of athero-
genesis. Early atherosclerosis is characterized by leukocyte
recruitment and expression of pro-inﬂammatory cytokines
[9,10]. Lesion formation starts with the attraction, recruitment
and activation of monocytes, endothelial cells, T lymphocytes
and smooth muscle cells accompanied with a local inﬂamma-
tion. Modulation of these inﬂammatory processes is very likely
to aﬀect progression of the disease. Macrophages are consid-
ered as the key cellular components of atherosclerotic lesions,
therefore factors that inﬂuence their presence and inﬂamma-
tory activity can also aﬀect progression of the disease.
A variety of macrophage functions related to immune regu-
lation are known to be involved in atherogenesis. PPAR-c was
described as a general negative regulator of macrophage acti-
vation and has also been shown to reduce inﬂammatory reac-
tions based on data showing that PPAR-c agonists, like the
prostanoid 15-deoxy-D12,14-prostaglandin J2 (15d-PGJ2) or
synthetic activators like TZDs inhibited the expression of
inﬂammatory cytokines and other molecules.
It was also shown in PPAR-c-deﬁcient macrophages that the
receptor is not essential for PPAR-c ligands to exert anti-
inﬂammatory eﬀects in macrophages [14]. Expression of pro-
inﬂammatory genes is also inhibited by natural and synthetic
ligands in both wild-type and macrophage-speciﬁc PPAR-c
conditional knockout mice [63,64]. Nevertheless, recently a
possible molecular mechanism responsible for PPAR-c-medi-
ated inhibition of inﬂammatory gene expression has beenreported demonstrating that ligand-induced SUMOylation of
PPAR-c targets the receptor to a co-repressor complex on
inﬂammatory gene promoters [65].
A reciprocal regulation was shown to exist between inﬂam-
mation and LXR-mediated lipid metabolism. LXR activators
inhibit the expression of inﬂammatory mediators [23] and
microbial compounds block the induction of LXR target genes
[24]. This model provides a possible scenario how the theory of
pathogen-evoked atherosclerosis and the cholesterol metabo-
lism can be integrated. LXR, similarly to PPAR-c has been
reported as target for SUMOylation-mediated trans-repression
[66]. So, both PPAR-c and LXR interfere with inﬂammatory
processes and generally inhibit inﬂammation, which may be
important during atherogenesis in the developing lesion.7. Macrophage development, adhesion and migration: steps
towards atherosclerosis
Beside the general eﬀects of PPAR-c and LXR on inﬂamma-
tion, several mechanisms are known to exist where nuclear
receptors regulate various aspects of the inﬂammatory reac-
tions. In this chapter we summarize these checkpoints during
atherosclerosis and the possible involvement of PPAR-c and
LXR in modulating these processes at the macrophage level.
Development of macrophages is driven by monocyte colony-
stimulating factor (M-CSF). It also augments SR-A, cytokine
and growth factor expression and serves as a survival stimulus.
Mice deﬁcient in M-CSF are relatively resistant to atheroscle-
rosis [67,68]. Both granulocyte-macrophage and granulocyte
colony-stimulating factors (GM-CSF and G-CSF) increase
lesion formation when administered to ApoE knockout mice
[69–71]. At the same time GM-CSF deﬁciency reduces
PPAR-c expression and aggravates atherosclerosis in ApoE
knockout mice [70]. It was reported that PPAR-c promotes
diﬀerentiation of macrophages [11] but it is not required for
macrophage development per se [14].
Pro-inﬂammatory cytokines and high cholesterol level in-
duce adhesion molecule expression on endothelial cells, like
vascular cell adhesion molecule-1 (VCAM-1) [72]. VCAM-1,
P- and E-selectin contributes to atherosclerosis by recruiting
monocytes to the lesion as it was demonstrated by smaller fatty
streak formation in VCAM-1 or P/E-selectin and LDLR-deﬁ-
cient mice [73–75].
Following their adherence to endothelial cells, monocytes
are attracted to inﬂammatory sites by a family of chemoattrac-
tant cytokines known as chemokines (CC). The major signal
for monocytes is MCP-1 (Fig. 2). It is known that LDLR-deﬁ-
cient mice lacking also MCP-1 [76] or deletion of its receptor
CCR2 in ApoE null mice make them highly susceptible to ath-
erosclerosis [77]. IL-8 exerts similar role in attracting leuko-
cytes to the lesion [78]. Atherosclerotic plaques also express
CX3CL1, which stimulates migration of monocytes into the
lesion [79,80]. Macrophage migration inhibitory factor (MIF)
is upregulated during atherosclerosis [81,82] and deletion of
it decreases intimal thickening in LDLR null mice [83]. MIF
has been reported recently as a ligand for chemokine receptors
CXCR2 and CXCR4 that control leukocyte recruitment dur-
ing atherogenesis [84]. PPAR-c represses transcription of
MCP-1 and its receptor CCR2 in macrophages regulating
recruitment of these cells to inﬂammatory loci in the colon
[19,85–88].
Fig. 2. Monocyte diﬀerentiation is an important step of atherogenesis.
As a ﬁrst step of lesion formation a disturbance in endothelium
function results in the accumulation of oxidized LDL (oxLDL) in the
sub-endothelial matrix. OxLDLs activate both endothelial cells and
circulating monocytes resulting in monocyte migration into the sub-
endothelial space in response to locally produced chemoattractant
molecules and cytokines. The further diﬀerentiation of intimal mac-
rophages is regulated by monocyte chemoattractant protein-1 (MCP-
1) and monocyte colony stimulating factor (M-CSF). The intimal
macrophages express chemokine receptor 2 (CCR2) which forwards
diﬀerentiation signals to cells. As a result macrophages take up oxLDL
via scavenger receptors (SR) and start to produce metalloproteinases
(MMPs), cytokines and reactive oxygen species (ROS). These pro-
cesses evoke a characteristic inﬂammatory response around lipid
accumulation by releasing inﬂammatory molecules to the environment
like MCP-1, which attract additional macrophages and other cell types
to the lesion. This process is accompanied with the induction of
vascular cell adhesion molecules (VCAM) on endothelial cells, which
facilitates the adhesion of monocytes.
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migration seems to aﬀect atherogenesis and based on in vivo
studies most of them function as an atherogenic factor. On
one hand PPAR-c enhances macrophage/foam cell develop-
ment and on the other hand it inhibits expression of molecules
involved in macrophage chemotaxis.8. Uptake of modiﬁed LDL by pattern recognition receptors
There are special pattern recognition molecules (scavenger
receptors [SR], Toll-like receptors [TLRs]) on the surface of
the macrophages originally involved in pathogen uptake,
which can also recognize and bind the altered structure of lipo-
proteins [89]. Several of these, SR-A and CD36, SR-B1 oxLDL
receptor-1, collectin 2, CXCL16 [90], stabilin 1, 2 and SR-F on
endothelial cells, are involved in the recognition of LDL or
oxLDL. The literature is controversial about the consequence
of deleting SR-A from mice. There are reports suggesting that
it reduces atherosclerosis in ApoE [91,92] or LDLR null mice
[93,94] although others did not detect signiﬁcant eﬀects in an-
other model of murine atherosclerosis (ApoE3 Leiden) [95].
CD36-deﬁcient macrophages are more resistant to foam cell
formation as shown in ApoE knockout mice [96,97] and by
using CD36 blocking antibodies [98]. Moore and colleagues
showed that the lack of SR-A or CD36 results in decreased
lipid accumulation in peritoneal macrophages whilst associ-
ated with increased lesion areas in ApoE null background
[99]. This could be explained by the fact that lipid uptake bySRs is an important step in the elimination of cholesterol via
reverse cholesterol transport. SR-B1 is expressed in the liver
and also in macrophages. It binds HDL, LDL, modiﬁed
LDL and if knocked out, atherosclerosis is increased in
ApoE-deﬁcient [100,101] or LDLR-deﬁcient mice [102]. Deﬁ-
ciency of TLR-2 or 4 signiﬁcantly reduced atherosclerosis in
both ApoE and LDLR knockout animals [103–105].
As detailed above, PPAR-c was reported to upregulate
expression of scavenger receptor CD36 [11,106,107] and down-
regulate SR-A in macrophages [108]. PPAR-c was also
reported to induce oxLDL receptor-1 in adipocytes resulting
in increased uptake of the lipoprotein [109]. PPAR-c agonists
attenuate CXCL16 expression in macrophages [110].
Scavenger receptors are important in the uptake of lipopro-
teins; they enhance uptake in the periphery and protect cells
from excess amount of oxidized lipids by scavenging them
towards reverse cholesterol transport but once this system is
overloaded lipids accumulate in macrophages and foam cells
are formed. Therefore, the presence of SRs is beneﬁcial under
‘‘normal’’ conditions but they turn into harmful molecules
during atherogenesis.9. Inﬂammatory cytokines: agitators of inﬂammatory milieu
Most cells present in an atherosclerotic lesion produce
pro-inﬂammatory cytokines like IFNc and TNF-a [10]. Cells
responsible for pro-inﬂammatory cytokine production (TH1
polarized cells) are the dominant cell types in atheromas in
contrast to TH2 cells that produce predominantly anti-inﬂam-
matory cytokines [9]. The dominant cytokines are IFNc,
IL-12, IL-15, IL-18 and TNF-a [111]. Deﬁciency of IFNc
signaling (IFNc receptor knockout) reduces [112] while admin-
istration of IFNc enhances atherogenesis in ApoE null mice
[113]. Deletion of IFNc in LDLR null animals resulted in ﬁnd-
ings consistent with this scenario [114]. Inhibition of TH1 sig-
naling with pentoxyphilline reduced lesion size [115]. IL-18-
deﬁcient animals developed reduced atherosclerosis in ApoE
knockout [116]. IL-12 has been reported as a pro-atherogenic
cytokine [117–121]. Blockade of IL-12 signaling by vaccination
attenuates atherosclerosis [122]. IL-12 also induces T-cell
recruitment to the plaque [123].
The role of TH2 cytokines is more controversial as shown in
both ApoE and LDLR knockout models [121,124]. This sug-
gests that both TH1 and TH2 responses are involved in the
pathogenesis of atherosclerosis with a predominant role for
the pro-inﬂammatory molecules in the pathogenesis. This is
also supported by the observation that C57Black/6 mice
(prone to TH1 responses) can develop atherosclerosis while
BALB/c mice (prone to TH2 immune responses) are relatively
resistant to atherogenesis [125,126]. Targeted deletion of the
transcription factor signal transducer and activator of tran-
scription 6 (STAT6) through which IL-4 regulates gene expres-
sion in BALB/c mice makes them susceptible to atherogenesis
[126]. Binding of CD40 ligand to its receptor CD154 induces
inﬂammatory response along with expression of pro-inﬂamma-
tory cytokines, MMPs, adhesion molecules and tissue factor
while inhibition of CD40 ligation reduces plaque size
[127–130].
PPAR-c agonists inhibited the expression of several pro-
inﬂammatory molecules, e.g. inducible nitric oxide synthase,
gelatinase B [12,16,131], inﬂammatory cytokines like TNF-a,
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of PPAR-c [106] and according to our observations PPAR-c
signaling seems to be part of the anti-inﬂammatory response
by intensifying processes driven by IL-4 and mitigating IFN-
c-, TNF-a-provoked pro-inﬂammatory reactions (Szanto
et al., unpublished data).
It was shown recently, that activation of LXR inhibits secre-
tion of pro-inﬂammatory molecules like inducible nitric oxide
synthase, IL-6, IL-1-b, TNF-a [23].
The anti-inﬂammatory cytokine IL-10 generates protective
signals against atherosclerosis shown in IL-10 deﬁcient mice
by increased and in IL-10 transgenic mice by decreased lesion
formation [136–138]. 15d-PGJ2 can inhibit IL-10 signaling in a
STAT3 dependent and PPAR-c-independent way [139].
Another anti-inﬂammatory cytokine, transforming growth
factor b (TGF-b) also inhibits atherosclerosis at several levels.
By inducing collagen synthesis it stabilizes the plaque and pre-
vents formation of the vulnerable plaque. Patients with athero-
sclerosis have less active TGF-b in their sera [140]. Stimulating
TGF-b signaling in mice reduces the formation of fatty
streaks, whilst blocking it with neutralizing antibody acceler-
ates disease progression in ApoE-deﬁcient mice [141].
PPAR-c agonists inhibit TGF-b-induced connective tissue
growth factor expression via Smad3 [142] or ﬁbronectin
expression [143–145]. PPAR-c can repress TGF-b1 gene
through induction of phosphatase and tensin homologue
deleted on chromosome 10 (PTEN) [146].
Inﬂammatoryprocesses at the lesion site elaborate growth fac-
tors frommacrophages,which stimulate smoothmuscle cell pro-
liferation and synthesis of extracellular matrix elements
resulting in the formation of the ﬁbrous cap.Narrowing of vessel
lumenanddisruptionof this plaque are themajor sources of clin-
ical outcomes in atherosclerosis, such as angina pectoris, myo-
cardial infarction and stroke. Destabilization of the ﬁbrous
cap is enhanced by secretion of matrix metalloproteinases
(MMPs), which are type IV collagenases and degrade collagens
of extracellular matrix in mammals. MMPs were also shown to
be expressed in atherosclerotic lesion at high level [147–153].
There is evidence to suggest that PPAR-c is capable of inhib-
iting extracellular matrix remodeling in fatty streaks. It inhibits
expression of MMP-9 secretion [154,155]. Interestingly, LXR
can also repress MMP-9 expression [156]. These data suggest
that nuclear receptors regulate matrix degradation during late
atherosclerosis and also inhibit the formation of vulnerable
plaque and subsequently thrombosis.10. Involvement of adaptive immune response in atherogenesis
Dendritic cells (DCs) are professional antigen-presenting
cells derived from monocytes or other myeloid progenitors
and have been implicated in lesion progression. S-100 positive
DCs are present at lesion sites [157]. CCR7 the main chemo-
kine receptor regulating DC migration is expressed in the
lesion [158]. Recently, a speciﬁc group of T-cells, natural killer
T-cells (NKT-cells) have been detected in the atherosclerotic
lesion. These cells are characterized by the expression of
Va14Ja281-containing T-cell receptor (TCR) a-chains and rec-
ognize lipid antigens presented by CD1d molecules. Lack of
CD1d in ApoE null mice decreases atherosclerosis [159,160].
This suggests a novel crosstalk between lipid molecules and
the immune system at the level of DC function.PPAR-c has been implicated in several functions of DCs.
Activation of the receptor change the expression of co-stimula-
tory molecules on DCs with reduced capacity to induce lym-
phocyte proliferation and inhibits migration by decreasing
MCP-2, CCR7, EBI1 ligand chemokine [161,162]. Activation
of PPAR-c leads to reduced stimulation of DCs by TLR ago-
nists [163]. Furthermore, PPAR-c via induction of retinoic
acid synthesis induces CD1d expression in DCs resulting in
NKT cell proliferation and possibly altered lipid presentation
by CD1 molecules [164,165]. Absence of PPAR-c in DCs
increases their immunogenicity [166]. LXR also alters DC phe-
notype by decreasing IL-12, increasing IL-10 secretion and
blocking its T-cell stimulatory ability [167].
A recent study demonstrated that regulatory T-cells (Tregs)
reduced atherosclerosis when transferred, while depletion of
these CD25+ cells increased pathogenesis [168,169]. Transfer
of Tregs into ApoE knockout mice attenuates atherosclerosis
[170]. PPAR-c-expressing, but not PPAR-c null Tregs were
shown to prevent colitis suggesting a role for PPAR-c in regu-
lating immune responses through Tregs [171].11. Perspectives
PPARs and LXRs are known as ligand-regulated transcrip-
tion factors that play central regulatory roles in lipid uptake,
metabolism and eﬄux. Importantly, they are also implicated
in the regulation of inﬂammatory reactions. PPARs and LXRs
are activated by fatty acids, oxLDL, arachidonic acid metabo-
lites like eicosanoids, prostaglandins, leukotriens and oxidized
cholesterol, respectively. Majority of these natural ligands are
derived from the metabolism of unsaturated fatty acids and
cholesterol, therefore disorders of lipid consumption and
processing can inﬂuence transcriptional activity of PPAR
and LXR-regulated genes. Here, we provided a synopsis of
how the regulation of lipid homeostasis and inﬂammation is
interlaced by macrophages within the artery wall during ath-
erogenesis. PPAR-c is an inﬂammatory mediator controlling
many aspects of the inﬂammatory program with a net anti-ath-
erogenic consequence. However we have to note that some of
the anti-inﬂammatory eﬀects assigned to PPAR-c activators
are receptor-independent and inﬂammatory processes posi-
tively regulated by PPAR-c are still elusive. Much less is
known about LXR in inﬂammation but based on our current
knowledge we can assume further important ﬁndings concern-
ing the role of LXR in DC and lymphocyte functions.
Although majority of PPAR- and LXR-induced cellular
events result in anti-atherogenic processes, some eﬀects are
predicted to be atherogenic at the early stage of atherogenesis.
Activation of PPARs and LXRs by exogenous ligands can be
easily a ‘‘poison hath residence and medicine power’’, since it
can result in multiple changes in gene expression proﬁle of le-
sion macrophages and cells of the artery wall. Here, we should
refer to a very recent report on increased risk of myocardial
infarction and risk of death from cardiovascular causes in pa-
tients treated with a TZD, Rosiglitazone upon a meta-analysis
of previous studies. However, as the authors claim there were
limitations of this analysis and further comprehensive studies
are required [172].
The main perspective of PPAR and LXR research is to elu-
cidate the biological activities of each receptor subtype to facil-
itate the development of selective PPAR and LXR modulators
112 A. Szanto, T. R}oszer / FEBS Letters 582 (2008) 106–116that exhibit improved pharmaceutical beneﬁts in therapy of
atherosclerosis and metabolic syndrome. Also a huge challenge
for the future is the characterization of the species-speciﬁcity of
the identiﬁed processes, since many reported mechanisms are
seemed to be human or murine-speciﬁc. Furthermore, macro-
phage biology has also been shown to be more complex than
previously thought. The identiﬁcation of various monocyte
subtypes, diﬀerently activated macrophage subsets and the
involvement of DCs in metabolic disorders predict that much
remained to be discovered in this ﬁeld.
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